Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
about
Diet and Alzheimer’s disease risk factors or prevention: the current evidenceSrc homology-2 domain-containing protein tyrosine phosphatase (SHP) 2 and p38 regulate the expression of chemokine CXCL8 in human astrocytesGenetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathwaysThe role of macrophage migration inhibitory factor in Alzheimer's diseaseInsight into the Molecular Imaging of Alzheimer's DiseaseA deficiency in CCR2+ monocytes: the hidden side of Alzheimer's diseaseCCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunctionEbola: translational science considerationsCerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's diseasePharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malariaThe chemokine CCL2 activates p38 mitogen-activated protein kinase pathway in cultured rat hippocampal cellsFibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's diseaseCCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease.RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role.Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment.Chronic CXCL10 alters neuronal properties in rat hippocampal culture.Biomarkers of oxidative damage and inflammation in Alzheimer's disease.Increased astrocyte expression of IL-6 or CCL2 in transgenic mice alters levels of hippocampal and cerebellar proteins.Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease.Clinical phenotypes and genetic biomarkers of FTLD.Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview.Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine inhibit TNF-α and CXCL10 production from activated primary murine microglia via A2A receptors.Correlation between serum RANTES levels and the severity of Parkinson's disease.Interleukin-8-251T > A, Interleukin-1α-889C > T and Apolipoprotein E polymorphisms in Alzheimer's disease.An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin.Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammationPreconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation.CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model.The "Alzheimer's disease signature": potential perspectives for novel biomarkers.Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research.Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer's Disease Patients from Healthy SubjectsCXCL8 protects human neurons from amyloid-β-induced neurotoxicity: relevance to Alzheimer's disease.Altered hippocampal synaptic transmission in transgenic mice with astrocyte-targeted enhanced CCL2 expression.The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.Increased production of inflammatory cytokines in mild cognitive impairment.Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease.sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.Multiple cytokines are involved in the early events leading to the Alzheimer's disease pathology
P2860
Q22241476-FFC2382E-F6F3-4C4D-8113-33501CA1316EQ24300097-A9082504-67B7-4F0A-9057-AA4279515747Q24629875-7A5224FB-FF3B-463A-A3E6-9C19DD28B4A1Q24634765-DB8443A2-B881-4B99-91E4-E67255B0B3FBQ26765945-9E9CCA52-702A-4076-A72B-63D1F145812AQ26997058-DA9B9A9B-FDDE-46DC-A696-36F0A639D050Q27346578-3BB09AAE-6BAF-4A63-A96C-F600F8CA8C33Q28082994-CE096BE6-9874-4D02-AA4E-9DBD73B07240Q28087176-BECD01E2-1F6D-49D8-A684-A49BFF7F7807Q28486022-9FAB2FED-A41F-4740-A60A-A83FA662DB74Q28581399-8BF4B88E-B900-4886-9496-55800F160D8AQ33287487-6006DF65-FD55-4617-AF5A-E7B676ABE10DQ33572146-D8EF1967-39F9-4E5E-90EC-20A85CD2BB7EQ33578739-B8D55E8C-DF20-42CB-83B9-044F8BDA4337Q33626656-291DA57C-2399-4BC3-AFCB-3F59FB2ECA3FQ33635559-7BAC78B8-C8A7-4D79-BED5-50C917ACA32FQ33771834-11E9B510-EE3A-46D0-A0FB-DC7B4033AF24Q34043811-A9C1338F-48C4-4E1B-A9E4-88EA7E864F7BQ34181135-D9D60DBD-8C70-49B9-B024-FDECE87873A5Q34243054-5CE9E9A0-B0C1-413F-B304-2FBEBD2589ABQ34277859-8D7773EF-94B0-4A30-B7DD-B9A44D2F6542Q34438204-DA3811F3-E5E1-42F3-98DA-ECAE157D2DF0Q34674936-E2356EC6-087C-45EF-A2FF-FE227A756652Q34813794-BF65445C-0573-43DC-838C-760CE55BA4FBQ34896681-F67E392B-AD0D-4A2B-8B5A-91B8F7C27B81Q35016567-27170E60-A757-4433-AA85-714DB58F73E5Q35025065-23C4A37E-3D3E-4D0B-AD2B-B142BF3FFAF9Q35043731-4C728616-EE40-44CB-BBBB-305650D75985Q35242410-C65C3427-DD51-4C06-A6B8-F6C3BA8CCE32Q35339326-BDBE1931-DA33-4F5A-A249-559132BF265BQ35542811-FA832489-F239-4B85-9BF0-168FB05BEDBEQ35556085-36245CB7-0FB7-4D10-98E2-BBDE76949E95Q35607653-67B463AF-A032-436D-B811-1D281E677B5AQ35607995-72C428F9-40FD-4F79-9CDD-EA52114EF276Q35743736-D58219A6-A171-4BC9-9715-464807340D6FQ35745168-CC76ED3F-833D-480B-A0AE-1D93C6A65407Q35792619-B61E382C-25A3-4975-A2C6-6132A4CFE2E2Q35931230-F9E46C0C-FE42-40F9-95AC-1B706CD20279Q35945633-3CAB81D0-4E64-4160-A49F-C0ACCE4DB431Q35954373-AB474CC5-A073-42A8-AC83-964E22D47C63
P2860
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
@ast
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
@en
type
label
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
@ast
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
@en
prefLabel
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
@ast
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
@en
P2093
P50
P1433
P1476
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
@en
P2093
Eliana Venturelli
Femke Bouwman
Ilaria Guidi
Niki Schoonenboom
P304
P356
10.1001/ARCHNEUR.63.4.538
P50
P577
2006-04-01T00:00:00Z